Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | FER | P16591 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18830778 | 0.85 | — | — | |
| SCHEMBL156862 | 0.73 | MAPT (0.41) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL29353131 | 0.73 | MAPT (0.41) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL24383177 | 0.68 | NOS2 (0.39) | GAAMAPTNOS2 | |
| SCHEMBL10196365 | 0.67 | GAA (0.36) | GAAMAPT | |
| SCHEMBL18830878 | 0.66 | PDGFRA (0.31) | PDGFRAFERLTKCDK8ACVR1 | |
| Piperazine SCHEMBL20876223 | 0.66 | MAPT (0.34) | GAAMAPT | |
| SCHEMBL16865960 | 0.66 | NOS2 (0.30) | NOS2 | |
| SCHEMBL168935 | 0.65 | PDGFRA (0.52) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL1996673 | 0.65 | MAPT (0.38) | MAOAMAOBPDGFRAFERLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730991-A | Novel fluorescent compound, preparation method thereof and application thereof in aspects of mitochondrial fluorescence imaging and viscosity detection | 苏州大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| CN-104311477-B | Nitrogen-containing heterocyclic compound and use thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-01-04 | — | — | CN | disclosed |
| EP-1587585-B1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | BOEHRINGER INGELHEIM INT (DE) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | FNIP1, FN1, TNNC1 | MAOA 1681/4885MAOB 1788/4885PDGFRA 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.